TREACE MEDICAL CONCEPTS, INC. (TMCI): Price and Financial Metrics

TREACE MEDICAL CONCEPTS, INC. (TMCI): $5.16

0.12 (+2.38%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

TMCI Price/Volume Stats

Current price $5.16 52-week high $27.41
Prev. close $5.04 52-week low $3.92
Day low $4.99 Volume 757,700
Day high $5.24 Avg. volume 843,479
50-day MA $9.90 Dividend yield N/A
200-day MA $11.81 Market Cap 319.96M

TMCI Stock Price Chart Interactive Chart >


TREACE MEDICAL CONCEPTS, INC. (TMCI) Company Bio


Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.


TMCI Latest News Stream


Event/Time News Detail
Loading, please wait...

TMCI Latest Social Stream


Loading social stream, please wait...

View Full TMCI Social Stream

Latest TMCI News From Around the Web

Below are the latest news stories about TREACE MEDICAL CONCEPTS INC that investors may wish to consider to help them evaluate TMCI as an investment opportunity.

Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference

Tuesday, January 9, 2024, at 3:45 pm Pacific TimePONTE VEDRA, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on T

Yahoo | December 19, 2023

Does the New Anti-Obesity Medicine Affect Treace Medical Concepts (TMCI)?

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here. In the quarter the fund returned -3.67% (net), compared to -7.32% return for the Russell 2000 Growth Index. Year-to-date the fund returned 11.56% (net) compared to 9.59% return for […]

Yahoo | December 7, 2023

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q3 2023 Earnings Call Transcript

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Good day and thank you for standing by. Welcome to Treace Medical Concepts Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to turn the conference over to your […]

Yahoo | November 12, 2023

Q3 2023 Treace Medical Concepts Inc Earnings Call

Q3 2023 Treace Medical Concepts Inc Earnings Call

Yahoo | November 10, 2023

Treace Medical Concepts Reports Third Quarter 2023 Financial Results

PONTE VEDRA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights: Revenue of $40.8 million in the third quarter, a 23% increase over same period last ye

Yahoo | November 9, 2023

Read More 'TMCI' Stories Here

TMCI Price Returns

1-mo -50.38%
3-mo -61.83%
6-mo -41.10%
1-year N/A
3-year -84.10%
5-year N/A
YTD -59.53%
2023 -44.54%
2022 23.34%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!